1. Taiwan Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
BioLASCO Taiwan Co. Ltd.

BioLASCO Taiwan Co. Ltd.

TTPEX:6662
28.50
TWD
-0.45
(-1.55%)
1.60EPS
18.62P/E
765.80MMarket Cap
BioLASCO Taiwan Co. Ltd.
TPEX:6662
(Taipei Exchange)

Recent

price

28.50

P/E

ratio

18.62

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
- -
- -
11.44
14.01
12.61
13.81
11.67
8.89
9.21
10.34
11.42
10.26
10.13
Revenue per Share
- -
- -
2
2.28
2.28
2.19
2.45
1.76
1.65
1.94
1.72
1.66
1.61
Basic EPS, GAAP
- -
- -
2.36
-1.25
3.07
5.03
-1.6
2.6
1.58
1.09
0.04
1.06
1.32
Free Cash Flow per Basic Share
- -
- -
1.97
1.24
1.71
1.89
1.9
2
1.6
1.5
1.65
1.5
- -
Dividend per Share
9.55
9.9
12.8
13.83
14.54
18.24
18.26
17.97
17.75
18.01
17.55
17.87
16.69
Book Value per Share
9.55
9.88
12.78
13.81
14.52
18.23
18.26
17.97
17.73
17.99
17.53
17.86
16.68
Tangible Book Value per Share
23
16
20
23
23
25
26
26
26
26
26
26
25
Basic Weighted Avg Shares
- -
- -
232
326
294
347
299
228
236
265
292
263
258
Sales/Revenue/Turnover
- -
- -
22.83
21.25
23.54
20.34
25.95
23.7
20.88
19.19
19.04
18.32
17.78
Operating Margin (%)
- -
- -
6
6
7
9
10
10
10
11
11
12
13
Depreciation Expense
- -
- -
40
53
53
55
63
45
42
50
44
42
41
Net Income, GAAP
- -
- -
15.07
18.26
19.19
20
20
20
20.38
19.76
19.83
14.4
14.47
Effective Tax Rate (%)
- -
- -
17.46
16.27
18.09
15.86
21.01
19.84
17.94
18.79
15.05
16.15
15.85
Profit Margin (%)
133
136
174
169
200
315
264
247
231
230
181
157
126
Working Capital
13
12
11
10
9
10
67
63
58
51
95
81
74
LT Debt
222
231
298
322
339
467
468
460
455
461
449
458
427
Total Equity
- -
- -
15.98
17.32
15.92
13.44
11.96
7.91
7.33
7.68
8.19
7.38
7.44
Return on Invested Capital (%)
- -
- -
14.78
16.54
15.62
13.32
12.41
8.56
8.22
9.77
8.45
7.97
8.16
Return on Capital (%)
- -
- -
15.31
17.11
16.08
13.64
13.43
9.73
9.25
10.86
9.67
9.35
9.56
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
13
13
13
LT Borrowings
79
76
73
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
26
26
26
Market Capitalization
794
743
766

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
211
207
221
Cash, Cash Equivalents & STI
136
129
141
Accounts Receivable, Net
35
43
40
Inventories
30
27
33
Total Current Liabilities
54
89
95
Payables & Accruals
- -
- -
- -
ST Debt
13
13
13
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.85%
-0.42%
1.86%
Free Cash Flow
- -
475.39%
2,806.55%
Net Income, GAAP
- -
-6.39%
-3.63%
Sales/Revenue/Turnover
- -
-1.54%
-10.2%
Total Cash Common Dividend
- -
-4.02%
-9.09%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
48
92
69
84
292
2025
60
70
63
69
263
2026
61
65
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.35
0.47
0.75
1.72
2025
0.17
0.5
0.32
0.66
1.66
2026
0.21
0.41
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.65
2025
- -
- -
- -
- -
1.5
2026
- -
- -
- -
- -
- -
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
BioLASCO Taiwan Co., Ltd. (6662.TWO) breeds and produces specific pathogen-free (SPF) laboratory animals, including outbreed stocks, inbred strains, and immune-deficient models of rats and mice; distributes disease model animals from sources such as The Jackson Laboratory and Marshall BioResources; supplies laboratory animal-related instruments, equipment, and consumables, encompassing IVC systems, ventilated housing, automated watering systems, transponders, chlorine dioxide generators, blood pressure measurement systems, analgesia and behavioral equipment, metabolism trackers, X-ray systems, cleaning workstations, isolation chambers, and foggers; and provides pathology and toxicology testing services, animal health diagnostics, serological kits, biological indicators, special animal model services, surgical services, foster breeding, and animal testing laboratory support. Founded in 2001 and headquartered at 3F., No. 267, Chongyang Rd., Nangang Dist., Taipei City, Taiwan, the company operates as a technology licensee of Charles River Laboratories for SPF animal production across Taiwan, China, Southeast Asia, India, and Thailand, where it maintains breeding centers, sales operations, and subsidiaries including HyLasco Bio-Technology (India) Pvt. Ltd. and BioRiver Co., Ltd. BioLASCO serves the life sciences research, biotechnology, and pharmaceutical development sectors, targeting academic institutions, contract research organizations, and drug developers with high-quality, internationally accredited SPF animals and related services; its Yilan Breeding Center holds full AAALAC International accreditation (sixth renewal achieved) and multiple SNQ national quality certifications. In recent developments, BioLASCO listed on the Taipei Exchange in 2018 following its OTC market debut; established an international-standard pathology and toxicology laboratory in 2017 with TAF ISO17025 accreditation; invested in India and Thailand subsidiaries in 2015-2016; formed a Special Animal Service Center; and in 2022 launched an advanced Animal Testing Laboratory to expand diversified services.